Article

Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.

Département de Biologie des Tumeurs, Institut Curie, 26 rue d'Ulm, 75231 Paris Cedex, France.
Anticancer research (impact factor: 1.73). 06/2009; 29(5):1475-82. pp.1475-82
Source: PubMed

ABSTRACT This retrospective analysis was designed to confirm the predictive role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type I (PAI-1) in the outcome of early stage, node-negative breast cancer patients.
Node-negative patients having not received adjuvant chemotherapy, and for whom frozen samples were available, were selected.
Among the 169 patients included, 56.8% presented with uPA >3 ng/mg of proteins and/or PAI-1 >14 ng/mg of proteins. The median follow-up was 73 months. Significant correlations were found between uPA and disease-free survival (p [univariate]=0.003; p [multivariate]=0.01), and between uPA, PAI-1, and uPA plus PAI-1 and distant relapses (p=0.002). No significant correlation was found between uPA/PAI-1 and the risk of locoregional recurrence.
This study demonstrated that uPA and PAI-1 are useful predictors of distant metastases in a subset of early stage, node-negative breast cancer patients.

0 0
 · 
0 Bookmarks
 · 
32 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

adjuvant chemotherapy
 
distant metastases
 
distant relapses
 
median follow-up
 
node-negative breast cancer patients
 
Node-negative patients
 
plasminogen activator inhibitor type
 
predictive role
 
retrospective analysis
 
significant correlation
 
Significant correlations
 
uPA
 
uPA/PAI-1
 
urokinase-type plasminogen activator